JP2011529886A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011529886A5 JP2011529886A5 JP2011521135A JP2011521135A JP2011529886A5 JP 2011529886 A5 JP2011529886 A5 JP 2011529886A5 JP 2011521135 A JP2011521135 A JP 2011521135A JP 2011521135 A JP2011521135 A JP 2011521135A JP 2011529886 A5 JP2011529886 A5 JP 2011529886A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- disease
- composition according
- dimethylpyridin
- difluoromethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- -1 1-cyclopropyl-2-methoxyethyl Chemical group 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- LGFBVFFBJBSDGC-UHFFFAOYSA-N 1,2-dihydropyrazine-5-carbonitrile Chemical compound N#CC1=CNCC=N1 LGFBVFFBJBSDGC-UHFFFAOYSA-N 0.000 claims 1
- PJMUNXORSUNUCV-OAHLLOKOSA-N 4-[(1s)-1-cyclopropyl-2-methoxyethyl]-6-[[6-(difluoromethoxy)-2,5-dimethylpyridin-3-yl]amino]-5-oxopyrazine-2-carbonitrile Chemical compound C1([C@@H](COC)N2C(C(NC=3C(=NC(OC(F)F)=C(C)C=3)C)=NC(=C2)C#N)=O)CC1 PJMUNXORSUNUCV-OAHLLOKOSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000029650 alcohol withdrawal Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8523008P | 2008-07-31 | 2008-07-31 | |
| US61/085,230 | 2008-07-31 | ||
| PCT/US2009/041793 WO2010014280A1 (en) | 2008-07-31 | 2009-04-27 | Pyrazinone modulator of corticotropin-releasing factor receptor activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011529886A JP2011529886A (ja) | 2011-12-15 |
| JP2011529886A5 true JP2011529886A5 (cg-RX-API-DMAC7.html) | 2012-05-24 |
| JP5396474B2 JP5396474B2 (ja) | 2014-01-22 |
Family
ID=40651774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011521135A Expired - Fee Related JP5396474B2 (ja) | 2008-07-31 | 2009-04-27 | 副腎皮質刺激ホルモン放出因子受容体活性のピラジノンモジュレーター |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7932256B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2303867B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5396474B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20110040870A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102171205B (cg-RX-API-DMAC7.html) |
| AR (1) | AR072639A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009277057A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011000754A (cg-RX-API-DMAC7.html) |
| TW (1) | TW201008926A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010014280A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| CA2889044A1 (en) | 2012-11-15 | 2014-05-22 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| CA2893801A1 (en) | 2013-01-30 | 2014-08-07 | F. Hoffmann-La Roche Ag | Lna oligonucleotide carbohydrate conjugates |
| KR20210064407A (ko) | 2014-01-21 | 2021-06-02 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 선천성 부신 과형성 치료를 위한 crf1 수용체 길항제 |
| PL3984523T3 (pl) | 2018-12-07 | 2026-02-02 | Neurocrine Biosciences, Inc. | Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy |
| US12383536B2 (en) | 2019-09-27 | 2025-08-12 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods of use |
| IT201900021216A1 (it) | 2019-11-14 | 2021-05-14 | Isagro Spa | Processo per la preparazione di derivati piridinici e corrispondenti piridil-formammidine |
| ES3039926T3 (en) | 2019-12-04 | 2025-10-27 | Neurocrine Biosciences Inc | Crf receptor antagonists and methods of use |
| CN112552184B (zh) * | 2020-12-18 | 2022-05-10 | 诚达药业股份有限公司 | 一种含环丙基手性胺盐酸盐的合成方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4270297A (en) * | 1996-09-16 | 1998-04-02 | Du Pont Pharmaceuticals Company | Pyrazinones and triazinones and their derivatives thereof |
| ATE307121T1 (de) * | 2000-02-16 | 2005-11-15 | Neurogen Corp | Substituierte arylpyrazine |
| HRP20031096A2 (en) * | 2001-06-12 | 2005-08-31 | Neurogen Corporation | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators |
| AU2003278542A1 (en) | 2002-11-21 | 2004-06-15 | Pharmacia & Upjohn Company Llc | Pyrazine compounds as crf modulators |
-
2009
- 2009-04-24 US US12/429,810 patent/US7932256B2/en active Active
- 2009-04-27 AU AU2009277057A patent/AU2009277057A1/en not_active Abandoned
- 2009-04-27 WO PCT/US2009/041793 patent/WO2010014280A1/en not_active Ceased
- 2009-04-27 CN CN2009801386016A patent/CN102171205B/zh not_active Expired - Fee Related
- 2009-04-27 MX MX2011000754A patent/MX2011000754A/es active IP Right Grant
- 2009-04-27 JP JP2011521135A patent/JP5396474B2/ja not_active Expired - Fee Related
- 2009-04-27 KR KR1020117002253A patent/KR20110040870A/ko not_active Withdrawn
- 2009-04-27 EP EP09789614.6A patent/EP2303867B1/en not_active Not-in-force
- 2009-07-22 TW TW098124751A patent/TW201008926A/zh unknown
- 2009-07-30 AR ARP090102928A patent/AR072639A1/es not_active Application Discontinuation
-
2011
- 2011-03-21 US US13/052,458 patent/US8372847B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015502951A5 (cg-RX-API-DMAC7.html) | ||
| MY147442A (en) | Imidazoquinolines as lipid kinase inhibitors | |
| JP2020502092A5 (cg-RX-API-DMAC7.html) | ||
| JP2017533968A5 (cg-RX-API-DMAC7.html) | ||
| JP2016503785A5 (cg-RX-API-DMAC7.html) | ||
| EP2312945A4 (en) | PURE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER | |
| JP2014513110A5 (cg-RX-API-DMAC7.html) | ||
| JP2008513516A5 (cg-RX-API-DMAC7.html) | ||
| WO2008062905A3 (en) | Heteromonocyclic compound and use thereof | |
| NZ604004A (en) | Pyridone and aza-pyridone compounds and methods of use | |
| EP2312946A4 (en) | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER | |
| JP2017524005A5 (cg-RX-API-DMAC7.html) | ||
| ZA201006868B (en) | Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease | |
| EP2288260A4 (en) | TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD | |
| EP2385951A4 (en) | PHOSPHORAMIDATE DERIVATIVES FROM GUANOSINE NUCLEOSIDE COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTIONS | |
| EP2173344A4 (en) | TREATMENT OR PROPHYLAXIS OF NEUROLOGICAL OR NEUROPSYCHIATRIC ILLNESSES BY OCULAR ADMINISTRATION | |
| JP2004517852A5 (cg-RX-API-DMAC7.html) | ||
| JP2005510473A5 (cg-RX-API-DMAC7.html) | ||
| PE20130457A1 (es) | INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT | |
| WO2008000469A3 (en) | Nicotinic agonists selective for the alpha7 receptor subtype, the process for the preparation thereof and pharmaceutical compositions therefrom | |
| JP2009510064A5 (cg-RX-API-DMAC7.html) | ||
| WO2008130678A3 (en) | Rosuvastatin intermediates and process for the preparation of rosuvastatin | |
| HK1206597A1 (en) | Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof | |
| JP2015529681A5 (cg-RX-API-DMAC7.html) | ||
| WO2008098985A3 (en) | Pharmaceutical composition for the treatment of il-8 mediated diseases |